Roivant Sciences
The two-year Rotational Analyst Program at Roivant Sciences begins in July 2027 and offers recent graduates four six‑month rotations across various teams and Vants. Analysts will own projects, contribute to investments, R&D, clinical trial recruitment, and strategic finance, gaining exposure to the biopharmaceutical business and its subsidiaries.
Headquarters
New York, New York, United States
Company Size
201-500 employees
Founded
2014
Roivant is a healthcare company focused on improving patient outcomes by rapidly developing and delivering innovative medicines and health technologies. It builds and partners with nimble, entrepreneurial subsidiaries called "Vants"—biotech and healthcare technology companies that operate with a platform approach to source specialized talent, align incentives, and deploy technology. Roivant supports drug development, licensing and commercialization across therapeutic areas using shared infrastructure and focused teams. Its model emphasizes speed, operational efficiency and scalable, tech-enabled capabilities to bring therapies to patients faster.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Roivant Sciences.
33% above the average for this role
A Roivant spinout bets on AI-designed drugs for immune conditions
Dec 10, 2025
Research & Development Rotational Program Associate
Pfizer
Business Rotational Leadership Development Program Analyst
PTC
Engineering Rotational Leadership Development (WERLD) Program
Whirlpool
Rotational Intensive Specialized Experience (RISE) Program
Stryker
Rotational Analyst Program
Federal Home Loan Bank of Chicago
Finance/Accounting Rotational Analyst – Enterprise Analyst Program
KeyBank